BSE:530019

Stock Analysis Report

Executive Summary

Jubilant Life Sciences Limited operates as an integrated pharmaceutical and life sciences company worldwide.

Snowflake

Fundamentals

Excellent balance sheet established dividend payer.


Similar Companies

Share Price & News

How has Jubilant Life Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 530019 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-3.0%

530019

1.1%

IN Pharmaceuticals

-0.06%

IN Market


1 Year Return

-28.6%

530019

-9.5%

IN Pharmaceuticals

4.9%

IN Market

Return vs Industry: 530019 underperformed the Indian Pharmaceuticals industry which returned -9.5% over the past year.

Return vs Market: 530019 underperformed the Indian Market which returned 4.9% over the past year.


Shareholder returns

530019IndustryMarket
7 Day-3.0%1.1%-0.06%
30 Day-0.3%6.2%1.9%
90 Day23.3%7.2%9.6%
1 Year-28.0%-28.6%-8.8%-9.5%6.9%4.9%
3 Year-21.1%-22.5%-14.0%-15.8%38.5%31.5%
5 Year289.3%276.7%-10.7%-13.4%41.8%29.1%

Price Volatility Vs. Market

How volatile is Jubilant Life Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Jubilant Life Sciences undervalued compared to its fair value and its price relative to the market?

7.6%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 530019 (₹503.85) is trading below our estimate of fair value (₹545.57)

Significantly Below Fair Value: 530019 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 530019 is good value based on its PE Ratio (13.3x) compared to the Pharmaceuticals industry average (15.7x).

PE vs Market: 530019 is poor value based on its PE Ratio (13.3x) compared to the Indian market (13.2x).


Price to Earnings Growth Ratio

PEG Ratio: 530019 is good value based on its PEG Ratio (0.8x)


Price to Book Ratio

PB vs Industry: 530019 is overvalued based on its PB Ratio (1.5x) compared to the IN Pharmaceuticals industry average (1.4x).


Next Steps

Future Growth

How is Jubilant Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

16.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 530019's forecast earnings growth (16.8% per year) is above the savings rate (7.6%).

Earnings vs Market: 530019's earnings (16.8% per year) are forecast to grow slower than the Indian market (18.8% per year).

High Growth Earnings: 530019's earnings are forecast to grow, but not significantly.

Revenue vs Market: 530019's revenue (6.6% per year) is forecast to grow slower than the Indian market (11.5% per year).

High Growth Revenue: 530019's revenue (6.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 530019's Return on Equity is forecast to be low in 3 years time (16.2%).


Next Steps

Past Performance

How has Jubilant Life Sciences performed over the past 5 years?

29.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 530019 has large one-off items impacting its financial results.

Growing Profit Margin: 530019's current net profit margins (6.5%) are lower than last year (9%).


Past Earnings Growth Analysis

Earnings Trend: 530019's earnings have grown significantly by 29.2% per year over the past 5 years.

Accelerating Growth: 530019's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 530019 had negative earnings growth (-23.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.1%).


Return on Equity

High ROE: 530019's Return on Equity (11.5%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Jubilant Life Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: 530019's short term assets (₹46.2B) exceeds its short term liabilities (₹21.4B)

Long Term Liabilities: 530019's short term assets (₹46.2B) exceeds its long term liabilities (45.3B)


Debt to Equity History and Analysis

Debt Level: 530019's debt to equity ratio (85.4%) is considered high.

Reducing Debt: 530019's debt to equity ratio has reduced from 173.2% to 85.4% over the past 5 years.

Debt Coverage: 530019's debt is well covered by operating cash flow (29.9%).

Interest Coverage: 530019's interest payments on its debt are well covered by EBIT (5.8x coverage).


Balance Sheet

Inventory Level: 530019 has a high level of physical assets or inventory.

Debt Coverage by Assets: 530019's debt is covered by short term assets (assets are 1x debt).


Next Steps

Dividend

What is Jubilant Life Sciences's current dividend yield, its reliability and sustainability?

0.89%

Current Dividend Yield


Dividend Yield vs Market

company0.9%marketbottom25%0.6%markettop25%2.4%industryaverage0.8%forecastin3Years1.0%

Current dividend yield vs market & industry

Notable Dividend: 530019's dividend (0.89%) is higher than the bottom 25% of dividend payers in the Indian market (0.58%).

High Dividend: 530019's dividend (0.89%) is low compared to the top 25% of dividend payers in the Indian market (2.43%).


Stability and Growth of Payments

Stable Dividend: 530019's dividends per share have been stable in the past 10 years.

Growing Dividend: 530019's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (11.9%), 530019's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 530019's dividends in 3 years are forecast to be thoroughly covered by earnings (8.3% payout ratio).


Next Steps

Management

What is the CEO of Jubilant Life Sciences's salary, the management and board of directors tenure and is there insider trading?

9.2yrs

Average management tenure


CEO

Hari Bhartia (63yo)

37.8yrs

Tenure

₹110,719,923

Compensation

Mr. Hari Shankar Bhartia, B.Tech serves as the Managing Director and Co-Chairman of Jubilant Biosys Limited and Jubilant Life Sciences Limited. Mr. Bhartia serves as a Managing Director of Jubilant Enpro,  ...


CEO Compensation Analysis

Compensation vs Market: Hari's total compensation ($USD1.54M) is above average for companies of similar size in the Indian market ($USD356.17K).

Compensation vs Earnings: Hari's compensation has been consistent with company performance over the past year.


Management Age and Tenure

9.2yrs

Average Tenure

54yo

Average Age

Experienced Management: 530019's management team is seasoned and experienced (9.2 years average tenure).


Board Age and Tenure

2.5yrs

Average Tenure

65.5yo

Average Age

Experienced Board: 530019's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: 530019 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buy₹2,689,79709 Sep 19
Shyamsundar Bang
EntityIndividual
Shares6,260
Max Price₹431.50
Buy₹4,306,75628 Aug 19
Shyamsundar Bang
EntityIndividual
Shares10,309
Max Price₹428.83
Buy₹2,454,77023 Aug 19
Shyamsundar Bang
EntityIndividual
Shares5,674
Max Price₹433.64
Sell₹141,359,99421 Aug 19
Mav Management Advisors LLP
EntityCompany
Shares310,000
Max Price₹456.00
Buy₹141,359,99421 Aug 19
Miller Holdings Pte. Ltd.
EntityCompany
Shares310,000
Max Price₹456.00
Buy₹1,086,09814 Aug 19
Shyamsundar Bang
EntityIndividual
Shares2,517
Max Price₹431.51
Buy₹4,943,63108 Aug 19
Shyamsundar Bang
EntityIndividual
Shares11,500
Max Price₹430.35
Buy₹4,417,90202 Aug 19
Shyamsundar Bang
EntityIndividual
Shares10,000
Max Price₹442.10
Buy₹311,999,95624 Jun 19
Miller Holdings Pte. Ltd.
EntityCompany
Shares650,000
Max Price₹480.00
Buy₹458,249,97021 Jun 19
Miller Holdings Pte. Ltd.
EntityCompany
Shares975,000
Max Price₹470.00
Sell₹463,661,21112 Jun 19
Rance Investment Holdings Limited
EntityCompany
Shares975,000
Max Price₹475.55
Buy₹463,661,21112 Jun 19
Miller Holdings Pte. Ltd.
EntityCompany
Shares975,000
Max Price₹475.55
Buy₹325,714,96831 May 19
Miller Holdings Pte. Ltd.
EntityCompany
Shares650,000
Max Price₹501.10
Sell₹325,714,96831 May 19
Cumin Investments Ltd.
EntityCompany
Shares650,000
Max Price₹501.10
Buy₹436,495,57522 May 19
Miller Holdings Pte. Ltd.
EntityCompany
Shares770,445
Max Price₹566.55
Sell₹340,874,97925 Mar 19
Rance Investment Holdings Limited
EntityCompany
Shares450,000
Max Price₹757.50
Buy₹340,874,97925 Mar 19
Miller Holdings Pte. Ltd.
EntityCompany
Shares450,000
Max Price₹757.50
Sell₹2,724,694,91620 Mar 19
Jubilant Organosys Ltd., ESOP
EntityCompany
Shares3,474,601
Max Price₹784.17
Buy₹2,389,364,03520 Mar 19
Jubilant Corporation
EntityCompany
Shares2,831,000
Max Price₹844.00
Sell₹389,699,98019 Mar 19
Cumin Investments Ltd.
EntityCompany
Shares450,000
Max Price₹866.00
Sell₹5,209,50019 Mar 19
Renu Khanna
EntityIndividual
Shares6,020
Max Price₹865.37
Buy₹389,699,98019 Mar 19
Miller Holdings Pte. Ltd.
EntityCompany
Shares450,000
Max Price₹866.00
Sell₹4,136,12713 Mar 19
Rajesh Srivastava
EntityIndividual
Role
Member of the Board of Directors
Whole-Time Director & CEO of Life Science Ingredients
Shares5,018
Max Price₹840.29
Sell₹497,802,47812 Mar 19
Cumin Investments Ltd.
EntityCompany
Shares650,000
Max Price₹765.85
Buy₹497,802,47812 Mar 19
Jubilant Corporation
EntityCompany
Shares650,000
Max Price₹765.85
Sell₹1,406,85711 Mar 19
Vimal Kulshrestha
EntityIndividual
Role
Senior Key Executive
Senior VP and Business Unit Head of Ethanol & Speciality Gases
Shares1,800
Max Price₹791.20
Sell₹3,859,39405 Mar 19
Rajesh Srivastava
EntityIndividual
Role
Member of the Board of Directors
Whole-Time Director & CEO of Life Science Ingredients
Shares5,000
Max Price₹771.88
Sell₹2,441,17410 Dec 18
Vimal Kulshrestha
EntityIndividual
Role
Senior Key Executive
Senior VP and Business Unit Head of Ethanol & Speciality Gases
Shares3,000
Max Price₹813.72

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Rajagopal Sankaraiah (60yo)

    CFO & Executive Director of Finance

    • Tenure: 17.2yrs
    • Compensation: ₹70.30m
  • Hari Bhartia (63yo)

    Co-Chairman & MD

    • Tenure: 37.8yrs
    • Compensation: ₹110.72m
  • Rajesh Srivastava (54yo)

    Whole-Time Director & CEO of Life Science Ingredients

    • Tenure: 1.8yrs
    • Compensation: ₹45.68m
  • Chandan Sengar (55yo)

    President of Life Science Chemicals

    • Tenure: 0yrs
  • Vimal Kulshrestha (54yo)

    Senior VP and Business Unit Head of Ethanol & Speciality Gases

    • Tenure: 0yrs
  • Arun Sharma (53yo)

    CFO (LSI) & Executive VP of Corporate Finance

    • Tenure: 0yrs
  • Umesh Mehta (53yo)

    Chief Information Officer

    • Tenure: 9.2yrs
  • Rajiv Shah

    Company Secretary & Compliance Officer

    • Tenure: 4.8yrs
    • Compensation: ₹8.43m
  • Sanjay Gupta (53yo)

    Senior VP & Head of Legal

    • Tenure: 5yrs
  • Ashok Varma (52yo)

    Vice President of Human Resuources

    • Tenure: 0yrs

Board Members

  • Shyam Bhartia (67yo)

    Chairman

    • Tenure: 0yrs
  • Sushil Roongta (69yo)

    Independent Non-Executive Director

    • Tenure: 2.5yrs
    • Compensation: ₹1.48m
  • Priyavrat Bhartia (43yo)

    Non Executive Non Independent Director

    • Tenure: 2.5yrs
  • Hari Bhartia (63yo)

    Co-Chairman & MD

    • Tenure: 37.8yrs
    • Compensation: ₹110.72m
  • Rajesh Srivastava (54yo)

    Whole-Time Director & CEO of Life Science Ingredients

    • Tenure: 1.8yrs
    • Compensation: ₹45.68m
  • Anant Pande (56yo)

    President of Manufacturing & Whole-Time Director

    • Tenure: 1.1yrs
    • Compensation: ₹12.15m
  • S. Sridhar (67yo)

    Independent Non Executive Director

    • Tenure: 5.2yrs
    • Compensation: ₹1.53m
  • Sudha Pillai (68yo)

    Independent Non Executive Director

    • Tenure: 6.2yrs
    • Compensation: ₹1.61m
  • Ashok Misra (72yo)

    Independent Non Executive Director

    • Tenure: 5.2yrs
    • Compensation: ₹1.49m
  • Vivek Mehra (64yo)

    Independent Non-Executive Director

    • Tenure: 2.5yrs
    • Compensation: ₹1.53m

Company Information

Jubilant Life Sciences Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Jubilant Life Sciences Limited
  • Ticker: 530019
  • Exchange: BSE
  • Founded: 1978
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹79.445b
  • Shares outstanding: 159.27m
  • Website: https://www.jubl.com

Number of Employees


Location

  • Jubilant Life Sciences Limited
  • 1A, Sector 16A
  • Noida
  • Uttar Pradesh
  • 201301
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
530019BSE (Mumbai Stock Exchange)YesEquity SharesININRJan 1992
JUBILANTNSEI (National Stock Exchange of India)YesEquity SharesININRJan 1992

Biography

Jubilant Life Sciences Limited operates as an integrated pharmaceutical and life sciences company worldwide. It has three segments: Pharmaceuticals, Life Science Ingredients, and Others. The company offers ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/20 12:48
End of Day Share Price2019/11/20 00:00
Earnings2019/09/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.